Cargando…

Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial

OBJECTIVE: To assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: This multicenter, open-label, randomized controlled trial comprised a 4-week run-in phase and a 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Peralta, Fernando, Abreu, Cristina, Fernández-Rubio, Elsa, Cotovad, Laura, Pujante, Pedro, Gaztambide, Sonia, Bellido, Diego, Menéndez Torre, Edelmiro, Ruiz-Valdepeñas, Santiago, Bello, Hugo, Valledor, Xoan, Pérez-González, Jesús, Ruiz-Valdepeñas, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797789/
https://www.ncbi.nlm.nih.gov/pubmed/36448932
http://dx.doi.org/10.2337/dc22-0525
_version_ 1784860758965747712
author Gomez-Peralta, Fernando
Abreu, Cristina
Fernández-Rubio, Elsa
Cotovad, Laura
Pujante, Pedro
Gaztambide, Sonia
Bellido, Diego
Menéndez Torre, Edelmiro
Ruiz-Valdepeñas, Santiago
Bello, Hugo
Valledor, Xoan
Pérez-González, Jesús
Ruiz-Valdepeñas, Luis
author_facet Gomez-Peralta, Fernando
Abreu, Cristina
Fernández-Rubio, Elsa
Cotovad, Laura
Pujante, Pedro
Gaztambide, Sonia
Bellido, Diego
Menéndez Torre, Edelmiro
Ruiz-Valdepeñas, Santiago
Bello, Hugo
Valledor, Xoan
Pérez-González, Jesús
Ruiz-Valdepeñas, Luis
author_sort Gomez-Peralta, Fernando
collection PubMed
description OBJECTIVE: To assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: This multicenter, open-label, randomized controlled trial comprised a 4-week run-in phase and a 6-week double-arm phase in which participants were randomly assigned into an active or masked mode. RESULTS: Fifty-five participants were evaluable (active group, n = 26, masked group, n = 29). The increase in time in range was higher in the active versus masked group (5.2% vs. −0.8%; P = 0.016). The active group showed a higher reduction in mean glucose, glucose management indicator, time above range, and high blood glucose index. On-time insulin doses increased in the active group and decreased in the masked group. CONCLUSIONS: Insulclock system use was associated with improved glycemic control, glycemic variability, hyperglycemia risk, and treatment adherence in people with uncontrolled type 1 diabetes.
format Online
Article
Text
id pubmed-9797789
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-97977892023-02-11 Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial Gomez-Peralta, Fernando Abreu, Cristina Fernández-Rubio, Elsa Cotovad, Laura Pujante, Pedro Gaztambide, Sonia Bellido, Diego Menéndez Torre, Edelmiro Ruiz-Valdepeñas, Santiago Bello, Hugo Valledor, Xoan Pérez-González, Jesús Ruiz-Valdepeñas, Luis Diabetes Care Novel Communications in Diabetes OBJECTIVE: To assess the efficacy of the insulin pen cap Insulclock on improving glycemic control, treatment adherence, and user satisfaction in people with type 1 diabetes. RESEARCH DESIGN AND METHODS: This multicenter, open-label, randomized controlled trial comprised a 4-week run-in phase and a 6-week double-arm phase in which participants were randomly assigned into an active or masked mode. RESULTS: Fifty-five participants were evaluable (active group, n = 26, masked group, n = 29). The increase in time in range was higher in the active versus masked group (5.2% vs. −0.8%; P = 0.016). The active group showed a higher reduction in mean glucose, glucose management indicator, time above range, and high blood glucose index. On-time insulin doses increased in the active group and decreased in the masked group. CONCLUSIONS: Insulclock system use was associated with improved glycemic control, glycemic variability, hyperglycemia risk, and treatment adherence in people with uncontrolled type 1 diabetes. American Diabetes Association 2023-01 2022-12-21 /pmc/articles/PMC9797789/ /pubmed/36448932 http://dx.doi.org/10.2337/dc22-0525 Text en © 2022 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Novel Communications in Diabetes
Gomez-Peralta, Fernando
Abreu, Cristina
Fernández-Rubio, Elsa
Cotovad, Laura
Pujante, Pedro
Gaztambide, Sonia
Bellido, Diego
Menéndez Torre, Edelmiro
Ruiz-Valdepeñas, Santiago
Bello, Hugo
Valledor, Xoan
Pérez-González, Jesús
Ruiz-Valdepeñas, Luis
Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
title Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
title_full Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
title_fullStr Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
title_full_unstemmed Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
title_short Efficacy of a Connected Insulin Pen Cap in People With Noncontrolled Type 1 Diabetes: A Multicenter Randomized Clinical Trial
title_sort efficacy of a connected insulin pen cap in people with noncontrolled type 1 diabetes: a multicenter randomized clinical trial
topic Novel Communications in Diabetes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797789/
https://www.ncbi.nlm.nih.gov/pubmed/36448932
http://dx.doi.org/10.2337/dc22-0525
work_keys_str_mv AT gomezperaltafernando efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT abreucristina efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT fernandezrubioelsa efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT cotovadlaura efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT pujantepedro efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT gaztambidesonia efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT bellidodiego efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT menendeztorreedelmiro efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT ruizvaldepenassantiago efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT bellohugo efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT valledorxoan efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT perezgonzalezjesus efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial
AT ruizvaldepenasluis efficacyofaconnectedinsulinpencapinpeoplewithnoncontrolledtype1diabetesamulticenterrandomizedclinicaltrial